Mckesson Corporation · NYSE:MCK
Mckesson — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
17 slides from Mckesson's conference presentation, Jan 14, 2025
Slide 1: McKesson Corporation J. P. Morgan Healthcare Conference
McKesson Corporation J. P. Morgan Healthcare Conference January 14, 2025 Brian Tyler Chief Executive Officer
Slide 2: Cautionary Statements
Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,”
Slide 3: Advancing Health Outcomes for All
Advancing Health Outcomes for All®
Slide 4: Accelerating the Enterprise: Sustaining Long-Term Growth and Value
Accelerating the Enterprise Sustaining Long-Term Growth and Value • Integrity & Inclusion • Respect Our Purpose: • Customer-first • Excellence Advancing Health Outcomes for All® • Accountability Our Strategic Focus and Growth Pillars: Focus Strengthen Modernize Enhance Oncology on People North Ameri
Slide 5: Delivering Sustainable Adjusted Operating Profit Growth
Delivering Sustainable Adjusted Operating Profit Growth FY25 Adjusted Operating Profit by Segment FY25 Segment Outlook 66% USP U.S. Pharmaceutical 9% to 11% growth Prescription Technology Solutions 11% to 15% growth 8% Low end of International Medical-Surgical Solutions 6% to 8% growth 19% MMS (10%)
Slide 6: Oncology Attracts Most Drug Investment and Innovation
Oncology Attracts Most Drug Investment and Innovation Drug Spend by Therapeutic Category: 2025 1 Strategic focus on Oncology, the largest therapeutic category measured by drug spend Differentiated Oncology offerings including practice management; real-world data, evidence, and technology; and clinic
Slide 7: Differentiated Oncology Platform Built Over Time
Differentiated Oncology Platform Built Over Time Onmark Core Ventures1 GPO Florida Cancer Specialists’ business Distributor of Community oncology Differentiated Oncology-focused Internally developed & administrative specialty Group Purchasing community specialty pharmacy oncology technology services
Slide 8: Expanding Our Oncology Platform
Expanding Our Oncology Platform ~$35B+ Revenue in FY25 Specialty Real-World Data, Clinical Trial Practice Distribution and Evidence, and Management Management Specialty Pharmacy Technology and Services Onmark® and Unity GPOs Leading distributor 2,750+ providers 3.1M+ patient records 250+ locations i
Slide 9: Leading Biopharma Services Solutions
Leading Biopharma Services Solutions Access 94 million times Enabled patient access to medication annually through RelayHealth Affordability $8.8 billion of out-of-pocket savings for patients annually Adherence >25% Improvement in patient adherence rate McKesson’s comprehensive suite of solutions en
Slide 10: Scaled Biopharma Services Platform
Scaled Biopharma Services Platform Leadership in biopharma services and solutions Prescription Technology Intelligent Network Solutions (RxTS) Pharmacy claims switch and Automated insurer drug Patient assistance Automated hub services Prescription price automated copay programs coverage authorizatio
Slide 11: Oncology and Biopharma Services are Key Growth Drivers
Oncology and Biopharma Services are Key Growth Drivers Track record of innovation and value creation Large, growing markets with significant unmet needs Scaled platforms Differentiated portfolio of assets and capabilities Strategically positioned for success 11 © 2025 McKesson Corporation. All right
Slide 12: Strategy Execution Delivering Earnings Growth and Value
Strategy Execution Delivering Earnings Growth and Value 17% Adj. EPS CAGR (FY20 to FY25F) $32.40 to $33.00 $27.44 $25.94 $23.69 $17.21 $14.95 FY20 FY21 FY22 FY23 FY24 FY25F 12 © 2025 McKesson Corporation. All rights reserved. See Supplemental Information for definitions and further non-GAAP informat
Slide 13: Disciplined Capital Allocation Framework
Disciplined Capital Allocation Framework Growth Return capital Maintain a strong investments to shareholders balance sheet Strategy-led investment Grow dividend as earnings Investment-grade balance sheet and free cash expand Strategic acquisitions Ample liquidity accelerate growth imperatives Share
Slide 14: Key Takeaways from Today
Key Takeaways from Today Diversified healthcare services company with leading positions in Oncology & Biopharma Services Executing on our strategy, leading to sustainable profit growth and cash flows Strong core distribution assets across North America Delivering shareholder value creation and Retur
Slide 15: McKesson
MCKESSON
Slide 16: Footnotes
Footnotes These notes refer to the financial metrics and/or defined terms presented on: Slide 4 – Accelerating the Enterprise; Sustaining long-term growth and value • Adjusted EPS is Adjusted Earnings per Diluted Share (Non-GAAP), defined as GAAP income from continuing operations attributable to McK
Slide 17: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Full Year Fiscal 2024, 2023, 2022, 2021, and 2020 McKESSON CORPORATION RECONCILIATION OF GAAP EPS (NON-GAAP) (in millions) Year Ended March 31, 2024 2023 2022 2021 2020 Earnings (loss) per diluted common share from continuing operations attributable to McKesson Corpor
McKesson — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix